Associated Papers
Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers.
Malhotra L et al.
Journal of Biomolecular Structure & Dynamics, 2025
Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (TP53) upon Hotspot Mutation p53 Arg248 by Comparative Computational Approach.
Balasundaram A et al.
International Journal of Molecular Sciences, 2022
Complete Models of p53 Better Inform the Impact of Hotspot Mutations.
Solares MJ et al.
International Journal of Molecular Sciences, 2022
Potential of rescue and reactivation of tumor suppressor p53 for cancer therapy.
Hibino E et al.
Biophysical Reviews, 2022
Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition.
Semenov O et al.
Frontiers in Molecular Biosciences, 2022
Semi-Synthesis of Small Molecules of Aminocarbazoles: Tumor Growth Inhibition and Potential Impact on p53.
Long S et al.
Molecules (basel, Switzerland), 2021
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Wang Z et al.
Molecular Cancer Research : Mcr, 2020
Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature.
Nandikolla AG et al.
Breast Cancer (dove Medical Press), 2017
Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
Shtraizent N et al.
International Journal of Environmental Research and Public Health, 2015
PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.
Li XL et al.
Oncotarget, 2015
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Mohell N et al.
Cell Death & Disease, 2015
Structural and sequential context of p53: A review of experimental and theoretical evidence.
Saha T et al.
Progress in Biophysics and Molecular Biology, 2015
Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Millis SZ et al.
Clinical Genitourinary Cancer, 2015
TP53 mutants in the tower of babel of cancer progression.
Bisio A et al.
Human Mutation, 2014
p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation.
Yamada T et al.
Molecular Pharmaceutics, 2013
SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
Demma M et al.
The Journal of Biological Chemistry, 2010
Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.
Grochova D et al.
Oncogene, 2008
Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
Cardellino U et al.
Mutagenesis, 2007
MUT-TP53: a versatile matrix for TP53 mutation verification and publication.
Soussi T et al.
Human Mutation, 2006
Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors.
Favis R et al.
Human Mutation, 2004
Discrimination of single amino acid mutations of the p53 protein by means of deterministic singularities of recurrence quantification analysis.
Porrello A et al.
Proteins, 2004
p53 mutations and expression in breast carcinoma in situ.
Lukas J et al.
The American Journal of Pathology, 2000
WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium.
Lukas J et al.
The American Journal of Pathology, 1997
Analysis of a protein-binding domain of p53.
Ruppert JM et al.
Molecular and Cellular Biology, 1993